BACKGROUND: Hepatocellular carcinoma (HCC) is one of the few cancers whose incidence continues to increase. The goal of the current study was to investigate the presentation and survival trends of patients with HCC presenting to a university hospital between 1998 and 2015. METHODS: Study data were ascertained by individual chart review with survival data also supplemented by National Death Index query up to December 31, 2015. Patients were divided into three 6-year groups by diagnosis date (1998-2003, 2004-2009, and 2010-2015). RESULTS: A total of 2106 consecutive patients with HCC were included. The majority of patients had either hepatitis C (56.7%) or hepatitis B (22.1%), but cases of nonalcoholic steatohepatitis HCC increased by 68% over the most recent time period. Screening/surveillance identified 61% of HCC cases, but only 31% of these patients underwent curative treatment, which did not increase significantly over time. The overall median survival was 29.8 months (2.48 years) and without improvement over time. On multivariable analysis, Asian or Hispanic ethnicity, meeting Milan criteria, and receiving any of the standard HCC treatments were found to be significantly associated with improved survival, but diagnosis time period and liver disease etiology were not. CONCLUSIONS: Over the last 18 years, the percentage of cases of nonalcoholic steatohepatitis HCC has increased but not overall survival. It is interesting to note that only 31% of patients with HCC identified via screening/surveillance received any curative treatment. Further research is needed to better understand the barriers to curative care for patients with HCC and the causes of the lack of improvement in survival in the more recent patient cohort. Cancer 2018;124:2588-98.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the predominant form of primary liver cancer, which represents the fifth most common cancer in men and the eighth most common in women in the United States. 1 As opposed to the majority of other cancers, incidence and death rates have been increasing for liver cancer in the United States over the past 2 decades. 1 HCC develops within the context of chronic liver disease and inflammation. Hepatitis C virus (HCV) infection is the leading cause of HCC in the United States, whereas hepatitis B virus (HBV) infection is the leading cause worldwide, particularly in regions of Asia and Africa. 2 Among cases of HCC in the United States, white, black, Hispanic, and Asian individuals have differing distributions of HCC etiologies, incidence, and outcomes. 3, 4 Results from the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked databases provided estimates of population-attributable risk factors for HCC, suggesting that chronic HCV, alcohol-related disease, and metabolic disorders were the most significant HCC risk factors for white, Hispanic, and black individuals, whereas chronic HCV and HBV were found for Asian individuals. 5, 6 However, Medicare-linked data are not generalizable for those aged <65 years, and the SEER registry alone does not include liver disease etiology.
In addition, risk factor distributions continue to change. For example, as obesity and other comorbidities have increased in prevalence in the United States, the prevalence of metabolic syndrome and subsequent risk of nonalcoholic steatohepatitis (NASH) have increased as well, making NASH currently the second leading indication for liver transplantation. [7] [8] [9] Conversely, the prevalence of viral hepatitis-related HCC has been decreasing with the widespread adoption of the HBV vaccine and improved antiviral therapies.
Therefore, the objectives of the current study were: 1) to evaluate trends in HCC presentation and treatment over the time span between 1998 and 2015, across different ethnicities and etiologies; and 2) to assess for changes in overall survival while controlling for other demographic and clinical risk factors.
MATERIALS AND METHODS

Study Design and Patient Population
We performed a retrospective cohort study of 2234 consecutive adult patients with HCC who were evaluated at Stanford University Medical Center between January 1998 and July 2015, for whom a diagnosis of HCC was made between 1998 and 2015. Patients first were identified via International Classification of Diseases, Ninth Revision (ICD-9) diagnosis query for HCC. Individual electronic medical records subsequently were reviewed and abstracted using a case report form. Patients were excluded if they were diagnosed with HCC before 1998 or if they had insufficient survival data (Fig. 1) .
This study was approved by the institutional review board at Stanford University in Stanford, California.
Definition of HCC Diagnosis Date
The date of HCC diagnosis was determined via cytologic and pathologic criteria from tumor biopsy or via noninvasive imaging criteria as described by the 2011 American Association for the Study of Liver Diseases guidelines.
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The cohort was separated into three 6-year groups by diagnosis date (1998-2003, 2004-2009, and 2010-2015) . 
Definition of Ethnicity and HCC Etiologies
Ethnicity categories were determined by mirroring the SEER database: non-Hispanic white (white), white Hispanic (Hispanic), Asian, and black. HCC etiologies were categorized into 1 of 4 categories as determined from hepatologist medical records: HBV, HCV, HBV-HCV coinfection, and nonviral etiology. Specifically, hepatitis B status was determined by the presence of hepatitis B surface antigen, HBV DNA, or a documented history of 
Definition of HCC Primary Treatment
HCC primary treatment was defined as the highest level of treatment received, categorized herein in decreasing order: liver transplantation, liver resection, curative locoregional therapy (eg, radiofrequency ablation, percutaneous ethanol injection), noncurative locoregional therapy (eg, transarterial chemoembolization), other treatment (eg, sorafenib, systemic chemotherapy), and no treatment (supportive care only).
Survival Outcomes
Survival was defined as the time between HCC diagnosis and the date of death or the date of last follow-up. Death and follow-up dates were obtained via chart review.
Patients not known to have died then were searched for in the National Death Index (NDI) registry up to the final 2015 report (December 31, 2015) . The NDI is a centralized database of death record information on file in state vital statistics offices. 13, 14 If a death date was obtained from either the medical record or the NDI, the patients were identified as deceased. Otherwise, patient survival was censored at the date of last follow-up.
Statistical Analysis
Descriptive statistics were reported as the percentage for categorical variables, as the mean 6 standard deviation for roughly normally distributed continuous variables, or as the median with the interquartile range for skewed continuous variables. Categorical variables were evaluated using the chi-square test. Analyses of normally distributed variables were performed using the Student t test or analysis of variance. Analyses of nonnormally distributed continuous variables were performed using nonparametric methods. Survival data were evaluated using Kaplan-Meier methods, and the log-rank test was used to compare survival among independent subgroups.
The Cox proportional hazards model was used to estimate the hazard ratios (HRs) relating risk factors to survival outcomes. The final multivariable model consisted of variables with clinical significance determined a priori (age, 15, 16 19, 20 and liver disease etiology [20] [21] [22] [23] [24] ) and variables that met significance in the univariable model. The final model estimated the HRs for diagnosis year groups, adjusting for ethnicity, HCC etiology, age, sex, tobacco and alcohol history, cirrhosis status, MELD score, Milan criteria status, and primary treatment modality. Overall, approximately 76% of the cohort did not have any missing data with regard to the final multivariable model, 22% had missing data for only 1 variable, 1.7% had data missing for 2 variables, and 0.3% were missing data for 3 variables. Apart from MELD score (20.8%; mostly attributable to missing international normalized ratio), the other covariates did not have missing data exceeding 2% of the cohort (see Supporting Table  1 ). Multiple imputation was performed before the multivariable analysis to deal with the missing data so that HRs could be estimated with minimized bias and minimized loss of power. The multiple imputation by chained equations algorithm was used to generate 50 imputed data sets under the assumption that the data were missing at random. The imputation process included the 11 variables in the multivariable model as well as 5 auxiliary variables (serum total bilirubin, serum creatinine, international normalized ratio, cumulative size of 3 largest tumors, and metastasis at the time of diagnosis). Statistical significance was defined as a 2-tailed P value < .05. All statistical analyses were performed using Stata software (version 14.2; StataCorp LLC, College Station, Texas).
RESULTS
A total of 74 patients were excluded for having HCC diagnosis dates before 1998, and 54 additional patients were excluded for insufficient survival data. In total, 2106 patients were included in the current study, with viral hepatitis (56.7% with HCV and 22.1% with HBV) accounting for nearly 80% of HCC etiologies (Fig. 1 ).
Baseline Characteristics
Baseline patient characteristics are shown in Table 1 Over recent periods, patients presented with a higher burden of comorbidities (Table 1) . 25 Although body mass index alone did not demonstrate significant differences over time for the ethnic subgroups, there were increases in estimated metabolic syndrome within each of the 3 major ethnic subgroups represented: white (7% in 1998-2003 to 15% in 2010-2015; P 5 .012), Hispanic (4% to 22%; P 5 .008), and Asian (3% to 17%; P < .001). Alcohol (44% in 1998-2003, 54% in 2004-2009 , and 68% in 2010-2015; P < .001) and tobacco (43% to 51% to 58%; P < .001) use history also increased with the time period, with significant trends for both among white patients and for alcohol history among Asian individuals.
Baseline clinical characteristics and laboratory values are shown in Table 2 . Data regarding surveillance leading up to HCC diagnosis were present for approximately 65% of the cohort. Among this subcohort, 61% were diagnosed under surveillance, 29% were diagnosed due to symptomatic findings, and 10% were found incidentally; this distribution did not differ statistically significantly (P 5 .10) across time periods. Missing data regarding surveillance were heavily weighted toward the periods for 1998 through 2004 and 2005 through 2009 (approximately 89% of missing surveillance data were patients diagnosed during these time spans); therefore, data regarding surveillance leading up to HCC diagnosis were not included in the Cox regression model, which used the multiple imputation method that is based on a missingat-random assumption. A history of decompensating events such as ascites and hepatic encephalopathy increased with more recent time periods, and the percentage of patients with Child class C disease increased from 12% to 16% during the period between 2010 and 2015. With the exception of bilirubin, aspartate aminotransferase, and alkaline phosphatase, the majority of laboratory values did not differ significantly across periods.
Tumor characteristics are shown in Table 3 . The size of the largest tumor, cumulative size of the 3 largest tumors, and number of tumors did not differ across periods, even when stratified by main ethnicity or etiology. Although the most recent period demonstrated an increase in vascular invasion from 8% to 15%, there was no significant change in the percentage presenting with metastasis noted. Figure 1 and Figure 2A illustrate the distribution of HCC etiology in the overall cohort and by time period, respectively. Compared with the earlier time periods, the percentages of patients diagnosed in 2010 through 2015 were greater for nonviral etiologies (25% vs 13%-16%) and less for HBV etiology (14% vs 24%-36%), whereas the percentages for HCV etiology remained approximately constant (47%-60%). The rise in nonviral etiologies was most evident among NASH (0.4% to 1.5% to 9.0%) and alcoholic (4.4% to 4.7% to 8.3%) etiologies. Figure 2B depicts primary treatment distributions per diagnosis year period stratified by etiology. Overall, as their primary treatment, 272 patients (13%) underwent liver transplantation, 280 (13%) underwent surgical resection, 102 (5%) received curative locoregional therapy, 900 (43%) received noncurative locoregional therapy, 50 (2%) received other treatment, and 497 patients (24%) received no treatment. Uninsured patients had higher rates of receipt of no treatment (29% vs 22%-23%; P < .001) compared with privately insured or those patients insured by Medicaid/Medicare. Over the time periods, the rates of curative treatment (ie, transplantation, surgical resection, and curative locoregional therapy) decreased (35% to 33% to 28%; P 5 .005), whereas the percentage of those receiving no treatment did not change significantly. No major etiology subgroup demonstrated a decrease in the percentage of patients receiving no treatment.
HCC Etiology and Primary Treatment
Among major etiology subgroups, only HCV etiology treatment distribution demonstrated a significant difference across time periods, secondary to the decrease in liver transplantation and increase in curative locoregional therapy percentages (Fig. 2B ). For patients with HCV etiology, the percentage of patients listed for transplantation decreased from between 41% and 44% to 29% (P < .001) in 2010 through 2015, alongside a decrease in the transplantation rate among listed patients (53%-58% to 29%; P < .001). For patients with non-HCV etiology, both the percentage undergoing transplantation and the percentage being listed for transplantation did not differ significantly across the time periods. 
Long-Term Overall Survival
The overall median survival was 29.8 months (2.48 years), with a mortality rate of 55.9% (1177 deaths). Using the reverse Kaplan-Meier method, 26 the median follow-up time was 49.8 months (4.15 years) .
Kaplan-Meier survival curves are shown for various subgroups in Figures 3 and 4 . Asian (5-year survival rate of 40%) and Hispanic (5-year survival rate of 36%) individuals had higher survival compared with white (5-year survival rate of 32%) and black (5-year survival rate of 20%) patients, with an overall log-rank P value of .0018. Although there was no significant survival difference among patients with HCV, HBV, and overall nonviral etiologies, separating the HBV cohort by cirrhosis status (302 of whom were cirrhotic and 163 of whom were noncirrhotic) demonstrated improved survival for patients with noncirrhotic HBV compared with patients with HCV, HBV with cirrhosis, or nonviral etiologies (5-year survival rate of 47% vs 33%-37%; log-rank P 5 .017). There was no difference in survival observed between those patients with private insurance and the Medicaid/ Medicare group (log-rank P 5 .91), but there was a significant decrease in survival associated with uninsured status (log-rank P < .001).
There was no difference in survival found across the time periods (Fig. 3C) , even when stratified by major ethnic or etiology subgroup. Figure 4 illustrates overall survival stratified by primary HCC treatment. There was no difference in survival observed across time periods within any treatment modality.
Predictors of Mortality
Results from Cox regression analyses are shown in Table  4 . Multivariable analysis demonstrated that Asian and Hispanic ethnicity, meeting Milan criteria, and receiving any of the standard HCC treatment modalities were significantly associated with improved survival, but diagnosis time period and liver disease etiology were not.
DISCUSSION
In this study, we characterized a large, diverse, consecutive cohort of patients with HCC, stratified by their diagnosis date from 1998 through 2015. Previous studies evaluating temporal trends in HCC presentation and management often were limited to population-based cancer registries such as the SEER database 16, 27, 28 that lacked detailed data regarding measures such as etiology, laboratory values, and clinical measures of liver function that may have significant effects on outcomes. A major finding of the current study confirms that although HCV continued to be the main cause of HCC through 2015, NASH continues to increase dramatically. In fact, in the current study, Another interesting finding was the increase in the number of patients diagnosed with HCC, which nearly doubled from 463 in the group of patients diagnosed between 1998 and 2004 compared with the 905 patients in the group diagnosed between 2010 and 2015. Because this outpaces the HCC incidence trends noted in the United States, 29 increasing surveillance may be another factor. However, this was difficult to assess in the current study because missing data regarding surveillance were heavily weighted toward the periods of 1998 through 2004 and 2005 through 2009. Among nonmissing data, the percentage of patients diagnosed via surveillance did not change significantly across time periods.
Furthermore, there was no increase in curative treatment. Although rates of 1 in 4 patients receiving no treatment were not outside the range reported by previous studies, 30 the lack of improvement over time is concerning. We found that the largest driver of decreased mortality by far was the receipt of HCC treatment: a patient who received any curative or locoregional treatment experienced an approximately 50% to 95% decrease in their mortality rate compared with no treatment, depending on the modality.
A disconcerting finding was the association of the most recent time period with proportionally fewer patients being listed for transplantation, and among those listed, fewer patients receiving a liver transplant. According to data from the Organ Procurement and Transplantation Network as of January 31, 2018, the number of liver transplantations performed altogether at the center were 431, 504, and 333, respectively for the time periods 50%. This suggests that although increasing effective donor scarcity likely is a driving factor, 31, 32 other changes such as improvements in nontransplantation HCC treatment options also may be contributory. Fewer patients undergoing transplantation also may be related to the increasing number of patients with NASH HCC, because patients with NASH were found to be less likely to receive a liver transplant among patients with chronic liver disease, 9, 22 possibly secondary to increased comorbidities and/or slower disease progression compared with patients with HCC of HCV and alcoholic liver disease etiologies. 33 It is likely that decreases in the percentages of liver transplantation for patients with HCC will continue beyond 2015, with the United Network for Organ Sharing adopting a cap-and-delay revision on October 2015 to the HCC exception score policy, capping the exception score to 34 and delaying new exception score assignment by 6 months. 34 Ethnic percentages also changed significantly across the time periods, as percentages of Asian ethnicity decreased and the percentages of Hispanic and black ethnicities increased. These trends are similar to those observed in national-level studies using the SEER database. 29 This development likely is closely tied with etiological distribution changes, given that Asians represented >90% of the cases with HBV etiology in the current study cohort.
An encouraging finding from this study was the improved survival for Asian and Hispanic individuals compared with white individuals after controlling for etiology and clinical measures of liver function and tumor burden. Asians have been shown to have improved survival in other US studies, both in crude analyses and in analyses accounting for disease stage and treatment, although to the best of our knowledge, data regarding liver disease etiology generally are lacking, especially for the non-Medicare populations. 4 The robust improved survival may be due to higher rates of noncirrhotic HBV HCC; 4 however, the results of the current analysis, which accounted for etiology, cirrhosis, and hepatic function, suggested that there may be other factors, such as genetic differences, 35 that have significantly contributed to the improved survival noted among Asian individuals. The improved survival noted among Hispanic individuals in There are several limitations to the current study. First, this study was conducted at a single tertiary care center, and although the cohort was large, the study may be limited in its generalizability. Patients seen at tertiary care centers may have better access to potentially curative therapy, suggesting that survival at smaller centers may be even less than that observed herein. Second, the current study was a retrospective study. We minimized the risk of selection bias by selecting the cohort consecutively. In addition, the risk of misclassification or inaccuracy was lowered by completing individual chart review of relatively objective measures, such as diagnosis dates and overall survival. Third, missing data were present, mostly localized to laboratory or radiological characteristics. To mitigate this detriment, we used a multiple imputation method to estimate HRs for covariates with missing data. For our multivariable model, the majority of covariates were missing <2% of the total cohort, and highly correlated auxiliary variables were used to impute for MELD, the covariate with the most missing data.
Conclusions
The results of the current study confirmed that the etiological cause of HCC is changing over time, with NASH becoming a more prevalent cause. The increase in cases of NASH HCC is rising in parallel to our studied metabolic comorbidities, suggesting that further study is needed to understand the interaction of NASH and metabolic factors, and the appropriate treatment of each. We believe that the decrease in HBV HCC among Asian patients likely is due to the availability and use of well-tolerated oral anti-HBV medications since 1998. 38, 39 Asian and Hispanic patients with HCC demonstrated improved survival even when controlling for HCC etiology and liver function, indicating that other driving factors may be present.
However, despite the adoption of national and international guidelines in the early 2000s (which were updated again in 2011) for the surveillance of HCC, 11, 40 there was no improvement noted over time with regard to the use of curative treatment or long-term survival.
Although HCC diagnosis by surveillance was found to be strongly associated with decreased mortality (HR, 0.49; 95% confidence interval, 0.42-0.57), both the rates of diagnosis by surveillance and the percentages of curative treatments among those patients diagnosed by surveillance did not change significantly across the time periods. Percentages of patients receiving no HCC treatment did not decrease over time either.
By examining clinically relevant patient demographics, measures of liver disease, HCC etiology, and treatment, we demonstrated disparities that appear to be developing (rising number of nonviral HCC cases) or persisting (no improvement in overall survival) over the nearly 20-year time span. The findings of the current study further highlight areas of needed improvement, which include HCC screening and surveillance, early diagnosis, and curative treatment. Efforts should be targeted at identifying and treating high-risk populations, such as those individuals with chronic viral hepatitis, metabolic syndrome, and/or nonalcoholic fatty liver disease, to prevent the development of HCC as well as end-stage liver disease, for which to our knowledge the only truly curative treatment is liver transplantation, a modality that appears to be increasingly limited.
